SciELO - Scientific Electronic Library Online

 
vol.22 número3Efectos de la intervención desde terapia ocupacional sobre la percepción del dolor crónico y la calidad de vida en pacientes con artritis reumatoideEstudio a 2 años para medir la eficacia del fentanilo intranasal en pectina en el dolor irruptivo en enfermos con dolor no oncológico de edad avanzada índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista de la Sociedad Española del Dolor

versão impressa ISSN 1134-8046

Resumo

MUNOZ VELAZQUEZ, M.ª F. et al. Development of myasthenia gravis after botulinum toxin management in myofascial pain syndrome. Rev. Soc. Esp. Dolor [online]. 2015, vol.22, n.3, pp.102-105. ISSN 1134-8046.  https://dx.doi.org/10.4321/S1134-80462015000300003.

Myofascial pain syndrome is a painful muscle condition which is defined as local or referred pain associated with hypersensitive palpable nodules in the way of that muscle and is a frequent pathology in consultations on chronic pain. Botulinum toxin is an exotoxin produced by Clostridium botulinum, of which serogroups A, B and F have clinical utility (mainly type A- Botox®, Dysport®). This is one of the most potent neurotoxins and is administered compassionatelly in the treatment of myofascial pain syndrome. The toxin has a beneficial analgesic effect by reducing muscle hyperactivity but recent studies suggest that this neurotoxin may also induce analgesia by non-neuromuscular actions. Its use is not without risks. Adverse effects are related to the migration of the toxin and are usually mild or moderate and transient. There have been reports of prolonged muscle weakness and diseases like myasthenia gravis or Lambert Eaton syndrome triggered by the use of the toxin. We report a case of a male patient with myofascial pain syndrome whose psoas and quadratus muscles were treated with injections of botulinum toxin. Following the improvement in clinical muscle situation, repetitive diplopia and ptosis developed and the patient was diagnosed of myasthenia gravis. We review the pathogenesis of myofascial pain syndrome and myasthenia gravis and the use of botulinum toxin and relationships between them. We conclude that a detailed history is required prior to the use of botulinum toxin on patients with muscle pathology or signs of muscle weakness.

Palavras-chave : Myofascial pain syndrome; Myasthenia gravis; Botulinum toxin.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons